The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism
Open accessThe DOI matches its Crossref record; 138 of the 144 references it cites were found in a registry or an index; 96 of the 238 sources its claims cite were checked for support.
Abstract
Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels <0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (<65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.
Overview
CoChat Summary
TL;DR
The 2015 European Thyroid Association guidelines define endogenous subclinical hyperthyroidism (SHyper) biochemically as a persistently subnormal serum TSH with normal free thyroxine and triiodothyronine levels, divided into grade 1 (TSH 0.1–0.39 mIU/l) and grade 2 (TSH <0.1 mIU/l). They recommend treating older patients with grade 2 SHyper, considering treatment in older patients with grade 1 SHyper and younger symptomatic patients with grade 2 SHyper, and not treating younger asymptomatic patients with grade 1 SHyper.
Key findings
- SHyper prevalence varies widely, from 0.6 to 16%; in NHANES it was 0.7% with a TSH cutoff <0.1 mIU/l and 1.8% with a cutoff <0.4 mIU/l, and it can be as high as 15% in iodine-deficient subjects >70 years.
- Grade 2 SHyper carries higher risks than grade 1: progression to overt hyperthyroidism was 5–8% per year in grade 2 versus 0.5–0.7% over 7 years in grade 1, and one retrospective study reported progression in 20% of grade 2 versus 6.8% of grade 1 patients over 7 years (p < 0.001).
- Meta-analyses showed increased risks with SHyper, especially grade 2: incident atrial fibrillation HR 2.54 (95% CI 1.08–5.99) for grade 2 and 1.63 (95% CI 1.10–2.41) for grade 1; heart failure HR 1.94 (95% CI 1.01–3.72) for grade 2 and 1.31 (95% CI 0.88–1.95) for grade 1; total mortality HR 1.24 (95% CI 1.06–1.46); CHD mortality HR 1.84 (95% CI 1.12–3.00) for grade 2; fracture HRs were 1.52 (95% CI 1.19–1.93) for hip fracture, 1.42 (95% CI 1.16–1.74) for any fracture, and 1.74 (95% CI 1.01–2.99) for spine fracture.
- Treatment recommendations: treat patients >65 years with grade 2 SHyper (1/++0); consider treatment in patients >65 years with grade 1 SHyper (2/+00); suggest treating patients <65 years with persistent and/or symptomatic grade 2 SHyper (2/+00); and do not recommend treating young asymptomatic patients with grade 1 SHyper (2/+00). ATDs are first choice in young patients with Graves’ disease and grade 2 SHyper and in patients >65 years with Graves’ disease and grade 1 SHyper; RAI or surgery is preferred for older patients with toxic multinodular goitre or toxic adenoma.
Methods
- An ETA task force was formed in 2014 and performed a systematic literature review searching Medline for “subclinical hyperthyroidism” from May 1974 to July 2015, restricted to English-language reports but including translated articles, plus personal files and references.
- The task force used the GRADE system, rating recommendation strength as 1 (strong) or 2 (weak) and evidence quality as +++ (high, level A), ++0 (moderate, level B), or +00 (low, level C); because few randomized controlled trials were available, nonrandomized trials and expert opinions were also considered.
- Draft recommendations were posted on the ETA members-only website for 4 weeks, comments were incorporated, and the final document was approved by the ETA Guidelines Board and Executive Committee.
Limitations
- The paper states that there are no randomized prospective trials demonstrating that treatment of SHyper improves the associated cardiovascular and skeletal risks, and that two European trials were terminated because they did not complete recruitment.
- The paper states that in most prospective studies thyroid function was measured only at baseline, FT3 was measured in only a few cohorts, and the aetiology of hyperthyroidism was not considered.
- Evident from the text: many recommendations rely on observational cohort studies, meta-analyses of individual participant data, and expert opinion, with several recommendations graded weak (2) and/or supported by low-quality evidence (+00); treatment benefit itself remains unproven in randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Valid · 4 Not valid · 86 Not checked · 11 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent retrospective Danish cohort study, which was not included in the meta-analysis by Gencer et al. [75] , reported a trend for increased risk for major adverse cardiac events and HF with increasing degree of hyperthyroidism [77] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Risk of Heart Failure
What the sources say
- Disputedcites [77] Selmer C, Olesen JB, Hansen ML, et al: Sub- clinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endo- crinol Metab 2014; 99: 2372-2382. sourceExperimental — accuracy not yet measured
The Hyperthyroid states results report a trend with increasing hyperthyroidism for all-cause mortality, not for MACE or heart failure. They describe MACE risk as elevated in both subclinical and overt hyperthyroidism, while the discussion says the study could not demonstrate a clear dose-dependent relationship with decreasing TSH. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Radioiodine may induce hypothyroidism and ATDs may increase and reduce the rate of hypothyroidism when given in the week before or after radioiodine treatment, respectively [122] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Potential Adverse Effects during Treatment with ATDs, RAI and Surgery
What the sources say
- Disputedcites [122] Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B: Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007;10;334:514.10.1136/bmj.39114.670150.BE17309884 sourceExperimental — accuracy not yet measured
The Hypothyroidism section reports a risk ratio of 0.76 for hypothyroidism when antithyroid drugs were given before radioiodine treatment, indicating a possible reduction, not an increase; the confidence interval includes no effect. The Discussion also describes reduced hypothyroidism rates with antithyroid drugs given in the week before or after treatment. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cardiovascular symptoms are the most frequent indicators of mild thyroid hormone excess in the elderly, similar to overt hyperthyroidism [52,53] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Symptoms of Hyperthyroidism, Quality of Life, Cognitive Impairment or Dementia in Patients with SHyper
What the sources say
- Partly supportedcites [52] Sawin CT, Geller A, Wolf PA, et al: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-1252. sourceExperimental — accuracy not yet measured
The Discussion (p. 3) identifies atrial fibrillation as a manifestation associated with overt hyperthyroidism and finds that low thyrotropin is a risk factor for it in people aged 60 or older. The paper does not establish that cardiovascular symptoms are the most frequent indicators of mild thyroid hormone excess; it defines subclinical hyperthyroidism in an asymptomatic person (p. 1). (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [53] Cappola AR, Fried LP, Arnold AM, et al: Thy- roid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295: 1033-1041. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“At variance, two recent prospective studies did not find an association between low serum TSH levels and the risk of cognitive impairment and dementia or decreased functional capacity in the elderly [61,62] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Symptoms of Hyperthyroidism, Quality of Life, Cognitive Impairment or Dementia in Patients with SHyper
What the sources say
- Partly supportedcites [61] Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N, Welsh P, Jukema JW, Westendorp RG, Mooijaart SP: Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 2013; 8:e59199. sourceExperimental — accuracy not yet measured
The Discussion reports no association between subclinical thyroid dysfunction and cognitive performance or decline in participants aged 70–82 with vascular disease or risk factors. The Methods define low TSH as subclinical hyperthyroidism, so this supports the cognitive portion of the claim. The study did not report prospective risks of dementia or decreased functional capacity; its functional-capacity scores appear only as baseline characteristics in the Results. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [62] Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP; PROSPER Study Group: Sub- clinical thyroid dysfunction and functional ca- pacity among elderly. Thyroid 2014; 24: 208- 214. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, hyperthyroidism itself has been associated with a prothrombotic state [78,79] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Risk of Stroke
What the sources say
- Partly supportedcites [78] Squizzato A, Gerdes VE, Brandjes DP, Bül- ler HR, Stam J: Thyroid diseases and cere- brovascular disease. Stroke 2005; 36: 2302- 2310. sourceExperimental — accuracy not yet measured
The Conclusion says in vivo and in vitro studies suggest increased thrombotic risk in thyrotoxicosis, supporting a possible prothrombotic association. It also says evidence is insufficient to establish increased cardioembolic risk from hypercoagulability, so the claim should not be read as an established clinical association. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [79] Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, Faber J: Cardiovascu- lar events in thyroid disease: a population based, prospective study. Horm Metab Res 2011; 43: 653-659. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
123 more claims · 55 with their cited sources checked
Create a free account to see all 171 claims and every source verdict.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has widely been assumed that these associations are caused by subclinical hyperthyroidism with detrimental effects of excess thyroid hormone, for instance its proarrhythmic effect on the heart leading to AF, despite the fact that serum thyroid hormones are within reference range (1, 13–15, 29, 41, 42).”
From Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study (2016) · cites this paper as [41]
In the citing paper
“The European Thyroid Association recently reviewed these data and published guidelines for the treatment of subclinical hyperthyroidism, which are largely concordant with recommendations presented here (428).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [428]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Five meta-analyses assessed the risk of cardiovascular and allcause mortality in patients with SHyper [71,[89][90][91][92][93] .Two did not find a link between SHyper and mortality [89,90] , whereas four other meta-analyses found an association between SHyper and cardiovascular or all-cause mortality”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Cardiovascular Mortality and Coronary Heart Disease Events and Mortality
Reported 5 · recomputed 6
Citations
Cites
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., Franklyn, J. A., Hershman, J. M., Burman, K. D., Denke, M. A., et al. (2004) · JAMA · doi:10.1001/jama.291.2.228 · Cited by 1,800
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Self-citationLow Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259
Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Cooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039
Self-citation
Research works printed but not linked: 1
- Biondi/Bartalena/Cooper/Hegedüs/ Laurberg/Kahaly Eur Thyroid J 2015;4:149-163 DOI: 10.1159/000438750 162 · doi:10.1159/000438750162
Cited by
Items 101–200 of 316
Díez, J. J., & Iglesias, P. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2014-4589 · Cited by 10
Thyroid Hormone Abuse Among Elite Athletes
Handelsman, D. J., Gild, M. L., Clifton-Bligh, R. J., Speers, N., Kouzios, D., McMartin, M. C., & Desai, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad027 · Cited by 11
Selim, S., Mustari, M., Khan, T. A., & Kamrul-Hasan, A. B. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1322335 · Cited by 12
Einspieler, H., Walter, C., Hacker, M., Karanikas, G., & Tamandl, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-50118-z · Cited by 9
Kyrilli, A., Tacelli, N., Russo, L., et al. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0135 · Cited by 9
LIPID PROFILE IN SUBCLINICAL HYPOTHYROIDISM: A TWO CENTERS EXPERIENCE
QASIM, B. A. (2019) · Duhok Medical Journal · doi:10.31386/dmj.2019.13.1.6 · Cited by 9
Thyroid dysfunction on the heart: clinical effects, prognostic impact and management strategies
Mattesi, G., Michele, S. D., Mele, D., Rigato, I., Bariani, R., Fiorencis, A., Previtero, M., Sergani, A. A., Leoni, L., Bauce, B., et al. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2145 · Cited by 12
Negro, R., & Greco, G. (2023) · Endocrine · doi:10.1007/s12020-023-03301-1 · Cited by 7
Relationship between Euthyroidism and Muscle Mass and Strength: A Systematic Review
Greco, F., Moulton, C., Antinozzi, C., Lista, M., Luigi, L. D., Dimauro, I., & Sgrò, P. (2023) · International Journal of Sports Medicine · doi:10.1055/a-2093-2881 · Cited by 9
Subclinical thyroid dysfunction symptoms in older adults: cross-sectional study in UK primary care
McCahon, D., Haque, M. S., Parle, J., Hobbs, F. R., & Roberts, L. M. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x708065 · Cited by 8
Farvardin, M., mousavi, S. E., Zare, K., Bazdar, S., Farvardin, Z., & Johari, M. (2021) · Journal of Current Ophthalmology · doi:10.4103/joco.joco_174_20 · Cited by 8
Recurrence risk of autoimmune thyroid and endocrine diseases
Frommer, L., König, J., Chatzidou, S., Chionos, G., Längericht, J., & Kahaly, G. J. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101636 · Cited by 12
Self-citationA historical excursus of diagnostic methods for Hashimoto thyroiditis and Graves' disease
Trovato, M. C. (2020) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.19.04176-7 · Cited by 8
Ursem, S. R., Boelen, A., Hillebrand, J. J., den Elzen, W. P. J., & Heijboer, A. C. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0123 · Cited by 10
“Is there any reason to treat subclinical hypo and hyperthyroidism?”
Biondi, B. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.03.003 · Cited by 8
Self-citationCorona, G., Rastrelli, G., Dicuio, M., Concetti, S., Minnetti, M., Pivonello, R., Isidori, A. M., Sforza, A., & Maggi, M. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03208-3 · Cited by 11
Fadeev, V. V. (2020) · Clinical and experimental thyroidology · doi:10.14341/ket12474 · Cited by 12
Gottwald‐Hostalek, U., & Tayrouz, Y. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1978959 · Cited by 7
Secondary Hyperlipidemia and Atherosclerosis in Patients with Thyroid Pathology
Петрова, Е. Б., Николаевна, Ш. О., Статкевич, Т. В., Бельская, М. И., Плешко, А. А., Мычкова, А. В., & Митьковская, Н. П. (2023) · Кардиология в Беларуси · doi:10.34883/pi.2022.14.6.010 · Cited by 13
A model of functional thyroid disease status over the lifetime
Dzierlenga, M. W., Allen, B. C., Ward, P. L., M.A., H. J. C. I., & Longnecker, M. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219769 · Cited by 9
Radioiodine therapy of thyroid autonomy
Clerc, J. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.21.03340-9 · Cited by 7
Biondi, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99453-4 · Cited by 7
Self-citationThe public health burden of diabetes mellitus and thyroid disease: twin epidemics
Razvi, S. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01226-5 · Cited by 11
Suarez‐Zdunek, M. A., Arentoft, N. S., Krohn, P. S., Lauridsen, E. H. E., Afzal, S., Høgh, J., Thomsen, M. T., Knudsen, A. D., Nordestgaard, B. G., Hillingsø, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58544-3 · Cited by 7
Tamatea, J. A. U., Tu'akoi, K., Meyer-Rochow, G. Y., Conaglen, J. V., & Elston, M. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00111 · Cited by 6
Синдром тиреотоксикоза: новые клинические возможности коррекции тиреоидной дисфункции
Pankiv, V. І. (2020) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.1.2020.199129 · Cited by 6
Thyroid disease in the elderly
Limanova, Z. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.144 · Cited by 6
Metabolic Changes after Radioiodine Correction of Grade 1 and Grade 2 Subclinical Hyperthyroidism
Russo, L., Nguyen, T. N. H., Kyrilli, A., Robin, M., Lassen, P. B., Moreno‐Reyes, R., & Corvilain, B. (2021) · European Thyroid Journal · doi:10.1159/000512734 · Cited by 9
Subclinical hypothyroidism is associated with albuminuria in Japanese nondiabetic subjects
Toda, A., Hara, S., Tsuji, H., & Arase, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02220-9 · Cited by 7
Yang, J., Zheng, Y., Li, C., Liu, Y., Zhou, Q., Gao, J. L., Meng, X., Zhang, K., Wang, W., Shao, C., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab855 · Cited by 4
Novodvorský, P., & Allahabadia, A. (2017) · Medicine · doi:10.1016/j.mpmed.2017.05.013 · Cited by 11
Ceriotti, F., Fernández–Calle, P., Klee, G. G., Nordin, G., Sandberg, S., Streichert, T., Corrons, J. V., & Panteghini, M. (2019) · Laboratory Service · doi:10.17116/labs2019801193 · Cited by 5
Díez, J. J., Iglesias, P., García, A. A., Mataix, A. L., & Andreu, F. A. B. (2021) · European Geriatric Medicine · doi:10.1007/s41999-021-00544-x · Cited by 6
Gasser, R. W., Kocijan, R., Zendeli, A., & Resch, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030993 · Cited by 6
Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up
Carmona‐Hidalgo, B., Herrera‐Ramos, E., López, R. R., Nou‐Fontanet, L., Moreno, J. C., Blasco‐Amaro, J. A., Léger, J., Ortigoza‐Escobar, J. D., & NKX2-1-Related Disorders Guideline Working Group (2024) · PLoS ONE · doi:10.1371/journal.pone.0309064 · Cited by 6
Janovsky, C. C. P. S., Meneghini, V., Tebar, W. R., Martins, J. R. M., Sgarbi, J. A., Teixeira, P. D. F. D. S., Santos, I. S., Jones, S. R., Blaha, M. J., Toth, P. P., et al. (2025) · Metabolites · doi:10.3390/metabo15090606 · Cited by 4
Subclinical hyperthyroidism in the course of autonomous nodules — clinical evaluation
Rudzki, G., Lenart-Lipińska, M., Smoleń, A., Chrapko, B. E., & Matyjaszek‐Matuszek, B. (2019) · Endokrynologia Polska · doi:10.5603/ep.a2018.0088 · Cited by 5
Goichot, B., Lefebvre, F., Vinzio, S., Cailleux, A., Kuhn, J., Schneegans, O., Catargi, B., Gilly, O., Baltzinger, P., Meyer, N., et al. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0121 · Cited by 8
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6144 · Cited by 4
Na, S., Jang, W., & Lee, Y. (2024) · Sustainability · doi:10.3390/su17010137 · Cited by 4
Guarnizo-Poma, M., Paico-Palacios, S., Pantoja-Torres, B., Lázaro-Alcántara, H., Urrunaga‐Pastor, D., & Benites-Zapata, V. A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.023 · Cited by 5
Management of adenomas and toxic multinodular goiters with Iodine 131
Racaru, L. V., Grunenwald, S., Hindié, E., Taïeb, D., Clerc, J., & Zerdoud, S. (2020) · Médecine Nucléaire · doi:10.1016/j.mednuc.2020.09.001 · Cited by 4
Thyroid disorders associated with immune control point inhibitors
Fidilio, E., Navarro-González, E., Romero-Lluch, A. R., Iglesias, P., Gómez, J. J. D., Apiñániz, E. A., Mazo, E. S., & Zafón, C. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.10.004 · Cited by 7
Phowira, J., Coffey, K. L., Bartholomew, P. H., Vennart, N., Moreira, M., Emerson, H. M., Kennedy, D. W., & Weaver, J. U. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.843857 · Cited by 5
Karaca, Y., Karasu, M., Taşolar, H., & Evren, B. (2023) · Journal of Clinical Ultrasound · doi:10.1002/jcu.23459 · Cited by 5
Medical considerations in the ageing implant patient
Dave, M., Tattar, R., & Patel, N. (2023) · Oral Surgery · doi:10.1111/ors.12821 · Cited by 5
Impact of Thyroid Disease on Heart Failure
Stanciu, A. E., Zamfir‐Chiru‐Anton, A., Stanciu, M., & Gheorghe, D. C. (2017) · InTech eBooks · doi:10.5772/66283 · Cited by 4
Schmidt, M. C. (2017) · CME · doi:10.1007/s11298-017-5982-5 · Cited by 6
Kale, K., & Baviskar, B. P. (2018) · Thyroid Research and Practice · doi:10.4103/trp.trp_42_17 · Cited by 5
Piazera, B. K. L., Gomes, D. V., Vigário, P. D. S., Salerno, V. P., & Vaisman, M. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000075 · Cited by 6
Ycaza, A. E. E. D. (2018) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.12.001 · Cited by 6
CHANGES OF TSH, FT3 AND FT4 LEVELS IN PATIENTS WITH HYPERTHYROIDISM
Serdarević, N., Ćurlin, M., Dautbašić, A., Stanciu, A. E., Pradeep, D., & Durak-Nalbantić, A. (2024) · Zdravstveni glasnik · doi:10.47960/2303-8616.2024.1.9.94 · Cited by 2
Arrhythmien bei Schilddrüsenerkrankungen
Brenner, R., Bilz, S., Busch, S., Rickli, H., Ammann, P., & Maeder, M. T. (2024) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s00399-024-01030-0 · Cited by 3
Boyanov, M. (2020) · HORMONES · doi:10.1007/s42000-020-00203-z · Cited by 5
Kuzmanovska, S., & Miladinova, D. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.4318 · Cited by 3
Sambo, M., Ramos, R. J. A., Guerra, A. L., Montenegro, A. M. R., Fernández, L. G., Albarrán, O. G., & Megías, S. M. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.12.013 · Cited by 3
Campi, I., Perego, G. B., Ravogli, A., Santafede, F., Sileo, F., Dubini, A., Parati, G., Persani, L., & Fugazzola, L. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03071-0 · Cited by 3
Vinther, C. J., Poulsen, L., Nicolaisen, P., Obling, M. L., Brix, T. H., Hermann, A. P., Hegedűs, L. D., Jørgensen, N. R., Hansen, S., & Bonnema, S. J. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01907-2 · Cited by 5
Self-citationComparison of pathophysiology in subclinical hyperthyroidism with different etiologies
Deguchi-Horiuchi, H., Ito, M., Takahashi, S., Kousaka, K., Hisakado, M., Fukata, S., Kudo, T., Nishihara, E., Nishikawa, M., Miyauchi, A., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0497 · Cited by 3
Alwan, H., Luan, J., Williamson, A., Carrasco-Zanini, J., Stewart, I. D., Wareham, N. J., Langenberg, C., & Pietzner, M. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105306 · Cited by 3
Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation
Jay, M., Huan, P. W., Cliffe, N. C., Rakoff, J., Morris, E., Kavsak, P. A., Luthra, M., & Punthakee, Z. (2024) · Clinical Endocrinology · doi:10.1111/cen.15150 · Cited by 4
Negro, R., Greco, G., & Žarković, M. (2025) · Endocrine · doi:10.1007/s12020-025-04307-7 · Cited by 3
Toni, M., Pineda, J., Anda, E., & Galofré, J. C. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.06.003 · Cited by 4
Valencia, W. M., & Florez, H. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31831-8_22 · Cited by 3
Negro, R., & Greco, G. (2023) · Endocrine · doi:10.1007/s12020-023-03540-2 · Cited by 2
Impact of subclinical hyperthyroidism on bone
Koutroumpi, S., Stratigou, T., & Vlassopoulou, V. (2019) · Journal of Research and Practice on the Musculoskeletal System · doi:10.22540/jrpms-03-060 · Cited by 2
Дисфункция щитовидной железы и сердечно-сосудистые заболевания: состояние проблемы, пути решения
Netyazhenko, V. Z., & Liakhotska, A. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.4.2020.208487 · Cited by 3
Patient Population and Test Utilization for Thyroid Function in Local Clinics and Hospitals in Korea
Choi, R., Lee, S. G., & Lee, E. H. (2022) · Diagnostics · doi:10.3390/diagnostics12071638 · Cited by 4
Yu, C., Keen, J. A., & Shriver, E. M. (2022) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2022.03.008 · Cited by 2
The relationship between atherosclerotic disease and relapse during ATD treatment
Zhu, X., Zhang, Y., Zhao, X., Zhang, X., Ru, Z., Wu, Y., Yang, X., Hou, B., & Qiao, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1039829 · Cited by 3
Physiological effects of thyroid hormones in the aspect of comorbidity and healthy longevity
Troshina, E. A., & Terekhova, M. A. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-216-223 · Cited by 3
Zaman, G. S., Mir, M. A., Bashir, N., Kakaraparthi, V. N., & Zaman, F. A. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.2.17 · Cited by 2
Kalampounias, G., Varemmenou, A., Aronis, C., Mamali, I., Shaukat, A., Chartoumpekis, D. V., Katsoris, P., & Michalaki, M. A. (2024) · Cancers · doi:10.3390/cancers16142604 · Cited by 2
Spona, D. C., Frodi, D. M., Xing, L. Y., Kongebro, E. K., Haugan, K., Graff, C., Højberg, S., Krieger, D. W., Brandes, A., Køber, L., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae610 · Cited by 2
Atrial Fibrillation and Stroke: Updated Evidence on a Screening Program According to Serum TSH
Biondi, B. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae777 · Cited by 2
Self-citationNishijima, Y., Murakami, T., Higaki, N., Tani, J., & Noguchi, H. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0424 · Cited by 3
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2025) · Neuroendocrinology · doi:10.1159/000545525 · Cited by 2
EndoBridge 2024: pearls and highlights
Yıldız, B. O., Armeni, E., Balodimou, C., Biondi, B., Ciudin, A., Frühbeck, G., Fuleihan, G. E., Geer, E. B., Gillard, P., Gordon, C. M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00708-5 · Cited by 4
Self-citationWei, G., Shen, Y., Wang, X., Xiong, D., Zhang, L., Zhao, T., Li, X., Sun, M., Yu, S., Huang, X., et al. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.111723 · Cited by 2
Sylla, H., Camara, S. N., Barry, M. S., Habiboulaye, B., & Biro, D. (2021) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2021.9.2.0254 · Cited by 2
Maternal Euthyroid Hyperthyroxinemia May Reduce Preterm Birth Rate in Multiparous Women
Torremante, P., Kirschner, W., Muche, R., & Flock, F. (2017) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2017.76065 · Cited by 3
Dischinger, U., & Faßnacht, M. (2018) · Der Internist · doi:10.1007/s00108-018-0441-2 · Cited by 3
De novo coronary artery disease in graves’ disease. coincidence?
Shahsavari, D., & Zoll, B. E. (2018) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2018.1514934 · Cited by 2
Graves’ Disease and Cardiac Complications
Arslan, A., & Altay, H. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97128 · Cited by 2
Interference in thyroid function immunoassays: clinical consequences
Kuzmanovska, S., & Vaskova, O. (2020) · Macedonian Pharmaceutical Bulletin · doi:10.33320/maced.pharm.bull.2020.66.01.008 · Cited by 2
Epidemiology of Thyroid Disease and Swelling
Vanderpump, M. P. J. (2022) · doi:10.1093/med/9780198870197.003.0045 · Cited by 2
Investigational drugs in early stage clinical trials for thyrotoxicosis with hyperthyroidism
Gómez-Sáez, J.-M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1541086 · Cited by 2
Surgical treatment of patients with nodular toxic goiter
Zavhorodnii, S. M., Гатіа, М. С., Кубрак, М. А., & Danyliuk, M. B. (2021) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2021.3.229724 · Cited by 2
Bekov, E. K., Omarbekova, N., Kanatovna, A. M., Pozdnyakova, Y. V., Kabdollovna, M. A., Iltaevna, U. A., Toleutayevna, A. D., Minbaevich, A. O., & Sarsenbaevna, B. L. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6374 · Cited by 1
Endothelial dysfunction in subclinical hyperthyroidism: a randomised trial
Shakoor, S. A. K. K. A., Jiao, H., Ong, K. H., Tan, A., & Liew, H. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021215 · Cited by 1
Thyroid gland and heart: a cardiologist’s view on an endocrinological pathology. Review
Кondratiuk, V. Y., & Стахова, А. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-3-41 · Cited by 1
Subclinical Thyroid Dysfunction and Cardiovascular Disease
Lourenço, I., Correia-Chaves, J., Leite, A. R., Borges‐Canha, M., von Hafe, M., Vale, C., Leite-Moreira, A. F., & Neves, J. S. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ar230029 · Cited by 2
Novodvorský, P., & Allahabadia, A. (2025) · Medicine · doi:10.1016/j.mpmed.2025.06.012 · Cited by 2
Cooper, A., & Abraham, P. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000928 · Cited by 1
S3 guidelines on thyroid carcinoma: what’s new?
Kuczera, L., Müller, S. K., & Sievert, M. (2025) · HNO · doi:10.1007/s00106-025-01688-z · Cited by 1
Impact of thyroid disorders on flow-mediated dilation: a systematic review and meta-analysis
Zaffaroni, A., Gallo, D., Louka, S., Piantanida, E., Squizzato, A., & Tanda, M. L. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02770-7 · Cited by 2
Wang, S.-P., Zhou, Y.-F., Tang, C.-B., Huang, S.-S., Zhou, Y., Cao, Z.-P., & Chen, W. (2025) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v17.i12.111221 · Cited by 1
Non-salt Food Fortification Programs
Laurberg, P., & Rasmussen, L. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-49505-7_8 · Cited by 1
Self-citationThyroid disease in peri‑ and postmenopause period (literature review)
Zaidieva, Y. Z., Glazkova, A. V., & Kruchinina, E. V. (2020) · Medical alphabet · doi:10.33667/2078-5631-2019-4-33(408)-48-53 · Cited by 1
Schini, M., Stirling, R., Jacques, R., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14209 · Cited by 1
Metadata
- Authors
- Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J.
- Affiliations
- Federico II University Hospital (IT)
- University of Insubria (IT)
- Johns Hopkins University (US)
- 4Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
- Aalborg University Hospital (DK)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2015-08-26
- Volume
- 4
- Issue
- 3
- Pages
- 149-163
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC4637513
- OpenAlex
- W1562308323
- Semantic Scholar
- 818f295aa3f0f01a788efe5b483e264f688279b3
- Cited by
- 323
- References
- 144
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 34 · 2023: 27 · 2022: 32 · 2021: 39 · 2020: 40 · 2019: 16 · 2018: 38 · 2017: 30 · 2016: 20 · 2015: 3
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
- IrInSubria (University of Insubria) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- subclinical hyperthyroidism, Graves' disease, autonomously functioning thyroid nodules, multinodular goiter, thyroid-stimulating hormone, cardiovascular risk, atrial fibrillation, heart failure, fracture, elderly patients, treatment indications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.